Retatrutide: interactions

No retatrutide medicine is approved, so no approved label lists its interactions: Lilly states that “no retatrutide medicine has yet been approved by FDA or any other regulatory agency in the world”.[1] This page uses the label of tirzepatide (Zepbound), an approved Lilly drug, as a guide.[2] What follows from that label is about tirzepatide, a related drug, and is not established for retatrutide.

What the tirzepatide label warns about

• Insulin and drugs that raise insulin release. The label states that “concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia”.[2]
• Oral medicines. Tirzepatide “delays gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications”.[2]
• The pill. For the same reason, the label tells prescribers to “advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive”.[2]
• Surgery and sedation. The label notes that “pulmonary aspiration during general anesthesia or deep sedation has been reported in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures”, and says to “instruct patients to inform healthcare providers of any planned surgeries or procedures”.[2] The label is for tirzepatide, and the same has not been studied for retatrutide; telling the anaesthetist about any product sold as retatrutide is the cautious course.

Diabetes and insulin users

A case report in Cureus describes a patient with type 1 diabetes and gastroenteritis who had used an online-sourced product sold as retatrutide.[3] The patient's “recurrent hypoglycaemia required intravenous dextrose and insulin dose adjustment”.[3] The author is careful: “While causation cannot be established”, the “exposure may have contributed to symptom severity”.[3] The report also notes that with such products “composition, purity, and dosing accuracy may be uncertain”.[3]

When the product is not what the label says

In the UK, the MHRA reported that cases of “hypoglycaemic shock and coma, indicate that the pens may contain insulin rather than semaglutide”, and its safety bulletin recorded that “five cases reported that the Saxenda and Ozempic pens were confirmed to be falsified with insulin”.[4][5] Lilly alleges, as a party to its lawsuits, that some sellers' products contained “completely different active ingredients such as insulin, which could be life-threatening”.[6] Signs of low blood sugar after an injection are a reason to get help at once.

More on testing in Retatrutide from a research vial.

References

1. Eli Lilly and Company v. American Peptides LLC, No. 5:26-cv-04146 (W.D. La.), Complaint, filed 10/08/26 — US District Court, via CourtListener RECAP
2. ZEPBOUND (tirzepatide) injection, full prescribing information, revised 8/2026 — Eli Lilly and Company, via DailyMed (US National Library of Medicine)
3. Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis (Branine, Cureus 2026;18(8):e115260) — PubMed (Cureus)
4. MHRA warns of unsafe fake weight loss pens (26 October 2023) — Medicines and Healthcare products Regulatory Agency (GOV.UK)
5. Ozempic (semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products (Drug Safety Update, November 2023) — Medicines and Healthcare products Regulatory Agency (GOV.UK)
6. Lilly sues over 'illegal sales' of obesity drug retatrutide (August 2026) — pharmaphorum